Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 431

1.

Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?

Sanderson J, Ansari A, Marinaki T, Duley J.

Ann Clin Biochem. 2004 Jul;41(Pt 4):294-302. Review.

2.

Clinical pharmacology and pharmacogenetics of thiopurines.

Sahasranaman S, Howard D, Roy S.

Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. doi: 10.1007/s00228-008-0478-6. Epub 2008 May 28. Review.

PMID:
18506437
3.

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

Evans WE, Hon YY, Bomgaars L, Coutre S, Holdsworth M, Janco R, Kalwinsky D, Keller F, Khatib Z, Margolin J, Murray J, Quinn J, Ravindranath Y, Ritchey K, Roberts W, Rogers ZR, Schiff D, Steuber C, Tucci F, Kornegay N, Krynetski EY, Relling MV.

J Clin Oncol. 2001 Apr 15;19(8):2293-301.

PMID:
11304783
4.

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.

Gearry RB, Barclay ML.

J Gastroenterol Hepatol. 2005 Aug;20(8):1149-57. Review.

PMID:
16048561
5.

[Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].

Gisbert JP, González-Lama Y, Maté J.

Gastroenterol Hepatol. 2006 Nov;29(9):568-83. Review. Spanish.

PMID:
17129552
6.

The impact of thiopurine s-methyltransferase polymorphism on azathioprine-induced myelotoxicity in renal transplant recipients.

Kurzawski M, Dziewanowski K, Gawrońska-Szklarz B, Domański L, Droździk M.

Ther Drug Monit. 2005 Aug;27(4):435-41.

PMID:
16044099
7.

The thiopurines: an update.

Coulthard S, Hogarth L.

Invest New Drugs. 2005 Dec;23(6):523-32. Review.

PMID:
16267626
8.

Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease.

Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA.

Aliment Pharmacol Ther. 2003 Aug 15;18(4):395-400.

9.

TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease.

Stocco G, Martelossi S, Barabino A, Fontana M, Lionetti P, Decorti G, Malusà N, Bartoli F, Fezzi M, Giraldi T, Ventura A.

Dig Liver Dis. 2005 Dec;37(12):940-5. Epub 2005 Sep 30.

PMID:
16202677
10.
11.

Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.

Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.

Dig Liver Dis. 2008 Jun;40(6):425-32. doi: 10.1016/j.dld.2008.01.003. Epub 2008 Mar 4.

PMID:
18304898
12.
13.

Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.

Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM.

Intern Med J. 2005 Oct;35(10):580-5.

PMID:
16207256
14.

Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation.

Breen DP, Marinaki AM, Arenas M, Hayes PC.

Liver Transpl. 2005 Jul;11(7):826-33. Erratum in: Liver Transpl. 2005 Sep;11(9):1150.

15.

Clinical pharmacogenomics of thiopurine S-methyltransferase.

Zhou S.

Curr Clin Pharmacol. 2006 Jan;1(1):119-28. Review.

PMID:
18666383
16.

Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.

Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM.

Clin Pharmacol Ther. 1987 Jan;41(1):18-25.

PMID:
3467886
17.

Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.

Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X.

Aliment Pharmacol Ther. 2012 Jan;35(1):15-36. doi: 10.1111/j.1365-2036.2011.04905.x. Epub 2011 Nov 2. Review.

18.

Review article: thiopurines in inflammatory bowel disease.

Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW.

Aliment Pharmacol Ther. 2006 Sep 1;24(5):715-29. Review.

19.

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.

Schwab M, Schäffeler E, Marx C, Fischer C, Lang T, Behrens C, Gregor M, Eichelbaum M, Zanger UM, Kaskas BA.

Pharmacogenetics. 2002 Aug;12(6):429-36.

PMID:
12172211
20.

Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.

Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM.

Hepatogastroenterology. 2006 May-Jun;53(69):399-404.

PMID:
16795981
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk